Skip to main content
logo
KoBioLabs, Inc (KOSDAQ:348150)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,340.00
+25.00 (0.75%)
At close: Aug 11, 2026

KoBioLabs Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
71,21269,29268,35933,13811,6062,893
Revenue Growth
0.61%1.36%106.29%185.53%301.12%-36.98%
Gross Profit
52,49351,02546,79423,7097,9791,898
Operating Income
-8,856-9,651-6,905-18,458-20,292-16,337
Net Income
-3,728-6,330-5,298-13,853-21,921-15,382
Earnings Per Share
-192.06-326.14-276.00-748.00-1305.15-959.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
47,08547,10055,83066,24092,94788,685
Total Debt
16,63113,76916,54018,29413,7829,197
Net Cash (Debt)
30,45433,33139,29047,94679,16579,488
Net Cash Growth
-14.26%-15.17%-18.05%-39.43%-0.41%56.20%
Net Cash Per Share
1568.861717.362046.852587.954713.304953.80

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-2,572-5,784-4,355-13,832-16,556-12,481
Capital Expenditures
-396.12-296.78-1,640-15,133-14,683-5,512
Free Cash Flow
-2,969-6,081-5,995-28,966-31,239-17,993
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
73.71%73.64%68.45%71.55%68.75%65.61%
Operating Margin
-12.44%-13.93%-10.10%-55.70%-174.84%-564.66%
Pretax Margin
-5.73%-10.02%-6.11%-44.31%-198.44%-565.72%
Profit Margin
-5.24%-9.13%-7.75%-41.80%-188.89%-531.63%
FCF Margin
-4.17%-8.78%-8.77%-87.41%-269.17%-621.88%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
0.911.611.524.8516.48115.84